{
    "hands_on_practices": [
        {
            "introduction": "The cornerstone of planning any major liver resection is the quantitative assessment of the proposed future liver remnant (FLR). To prevent potentially fatal post-hepatectomy liver failure, the surgeon must ensure that the volume of the remaining liver is sufficient for the patient's metabolic needs. This exercise provides foundational practice in calculating the standardized future liver remnant (sFLR), a critical metric that normalizes the FLR against the patient's estimated total liver volume, allowing for a standardized comparison against established safety thresholds. ",
            "id": "4668293",
            "problem": "A $62$-year-old patient with bilobar colorectal liver metastases is being evaluated for a two-stage hepatectomy (TSH). Preoperative cross-sectional volumetry yields a measured Future Liver Remnant (FLR) of $420$ milliliters, and the patient’s Body Surface Area (BSA) is $1.80$ square meters. In surgical planning for staged liver resection and portal modulation such as Portal Vein Embolization (PVE), clinical decision-making relies on the Standardized Future Liver Remnant (sFLR), which is defined from core volumetric principles as a unitless fraction comparing the remnant to an estimate of the Total Liver Volume (TLV). For adults without chronic liver disease, a practical safety threshold often used is $0.20$ for sFLR in the context of major hepatectomy.\n\nUse the following well-validated body surface area-based regression to estimate the Total Liver Volume (TLV) in milliliters:\n$$ TLV = -794.41 + 1267.28 \\times BSA. $$\n\nFrom first principles, compute the sFLR for this patient using the definition that compares remnant volume to estimated total volume. Then, based on this value, determine whether $sFLR \\geq 0.20$ in the context of a normal, non-cirrhotic liver, and briefly indicate how this would inform the need for preoperative Portal Vein Embolization (PVE) versus proceeding to resection within a staged strategy.\n\nExpress the final sFLR as a unitless decimal and round your answer to $4$ significant figures. Do not include any percent signs in your answer.",
            "solution": "The problem is valid as it is scientifically grounded in established principles of surgical oncology and hepatobiliary surgery, well-posed with sufficient data, and objective in its formulation. We will proceed with the solution.\n\nThe problem requires the calculation of the Standardized Future Liver Remnant (sFLR) for a patient being considered for a two-stage hepatectomy (TSH). The clinical decision-making process for liver resection hinges on ensuring the Future Liver Remnant (FLR) is large enough to prevent post-hepatectomy liver failure. The sFLR normalizes the FLR volume against the patient's estimated Total Liver Volume (TLV), providing a standardized metric.\n\nFirst, we must estimate the patient's Total Liver Volume (TLV) using the provided body surface area-based regression formula:\n$$ TLV = -794.41 + 1267.28 \\times BSA $$\nThe patient's Body Surface Area (BSA) is given as $1.80$ square meters. We substitute this value into the equation:\n$$ TLV = -794.41 + 1267.28 \\times 1.80 $$\nPerforming the multiplication:\n$$ 1267.28 \\times 1.80 = 2281.104 $$\nNow, we complete the calculation for TLV, which will be in units of milliliters (ml):\n$$ TLV = -794.41 + 2281.104 = 1486.694 \\, \\text{ml} $$\nThis value, $1486.694$ ml, represents the estimated total volume of a healthy liver for this specific patient.\n\nNext, we compute the Standardized Future Liver Remnant (sFLR). The sFLR is defined as the unitless ratio of the measured Future Liver Remnant (FLR) volume to the estimated Total Liver Volume (TLV):\n$$ sFLR = \\frac{FLR}{TLV} $$\nThe problem provides the measured FLR as $420$ ml. Using our calculated TLV:\n$$ sFLR = \\frac{420}{1486.694} $$\nExecuting the division yields the sFLR value:\n$$ sFLR \\approx 0.28253106... $$\nThe problem requires this value to be rounded to $4$ significant figures. The first four significant digits are $2$, $8$, $2$, and $5$. The fifth digit is $3$, which is less than $5$, so we do not round up the last digit.\n$$ sFLR \\approx 0.2825 $$\n\nFinally, we must interpret this result in the clinical context provided. The safety threshold for sFLR in a patient with a normal, non-cirrhotic liver is stated to be $0.20$. We must determine if the calculated $sFLR$ meets or exceeds this threshold:\n$$ sFLR \\geq 0.20 $$\nSubstituting our calculated value:\n$$ 0.2825 \\geq 0.20 $$\nThis inequality is true. The patient's sFLR of approximately $0.2825$ is greater than the minimum required threshold of $0.20$.\n\nThis finding has direct implications for surgical planning. An adequate sFLR suggests that the liver remnant will be sufficient to support the patient's metabolic needs after the first stage of resection, minimizing the risk of postoperative liver failure. Therefore, a preoperative intervention designed to induce hypertrophy (growth) of the FLR, such as Portal Vein Embolization (PVE), is not indicated. The patient may proceed directly to the first stage of the planned two-stage hepatectomy. If the sFLR had been below $0.20$, PVE would have been necessary to increase the FLR volume to a safe level before proceeding with resection.",
            "answer": "$$\\boxed{0.2825}$$"
        },
        {
            "introduction": "While static volumetric assessment of the future liver remnant is essential, the dynamic quality of liver regeneration is an equally critical prognostic factor. After an intervention like portal vein embolization (PVE) is performed to induce hypertrophy, it is crucial to measure not just the final volume but also the rate at which the liver grew. This practice focuses on calculating the kinetic growth rate (KGR), a powerful tool that reflects the liver's true regenerative capacity and helps predict postoperative outcomes with greater accuracy. ",
            "id": "4668260",
            "problem": "A patient with bilobar colorectal liver metastases is being evaluated for a staged liver resection strategy combining portal vein embolization (PVE) followed by definitive hepatectomy. The clinical objective is to ensure sufficient hypertrophy of the future liver remnant before proceeding. The standardized future liver remnant (sFLR), defined as the ratio of the estimated future liver remnant volume to the standardized total liver volume, increased from $0.18$ immediately prior to PVE to $0.26$ four weeks afterward. Using the fundamental definition of a rate as the change of a quantity per unit time, compute the kinetic growth rate (KGR), defined here as the average rate of increase of $sFLR$ per week. Express your final $KGR$ as a decimal fraction per week and round to three significant figures. Then, based on your computed $KGR$, determine whether the criterion $KGR \\geq 0.02/\\text{week}$ is achieved in this patient.",
            "solution": "The problem statement is evaluated and determined to be valid. It is scientifically grounded in established principles of hepatobiliary surgery, specifically concerning staged liver resection and the clinical metric of kinetic growth rate ($KGR$). The problem is well-posed, providing all necessary definitions and data for a unique and meaningful solution. The language is objective and precise.\n\nThe task is to compute the kinetic growth rate ($KGR$) of the standardized future liver remnant ($sFLR$) and determine if it meets a specific clinical criterion. The $KGR$ is defined as the average rate of increase of the $sFLR$ per week.\n\nLet $S_i$ be the initial $sFLR$ prior to portal vein embolization (PVE), and let $S_f$ be the final $sFLR$ after a certain time period. Let $\\Delta t$ be this time period.\n\nFrom the problem statement, the given values are:\nInitial standardized future liver remnant, $S_i = 0.18$.\nFinal standardized future liver remnant, $S_f = 0.26$.\nThe time interval over which this growth occurred is $\\Delta t = 4 \\text{ weeks}$.\n\nThe kinetic growth rate, $KGR$, is defined as the average rate of change of the $sFLR$ over the time interval $\\Delta t$. This is mathematically expressed as the difference in $sFLR$ divided by the duration of the time interval:\n$$\nKGR = \\frac{\\Delta sFLR}{\\Delta t} = \\frac{S_f - S_i}{\\Delta t}\n$$\nSubstituting the given values into this equation:\n$$\nKGR = \\frac{0.26 - 0.18}{4 \\text{ weeks}}\n$$\nFirst, we calculate the change in the $sFLR$:\n$$\n\\Delta sFLR = 0.26 - 0.18 = 0.08\n$$\nNow, we compute the rate by dividing by the time interval:\n$$\nKGR = \\frac{0.08}{4} \\text{ week}^{-1} = 0.02 \\text{ week}^{-1}\n$$\nThe problem requires the final $KGR$ to be expressed as a decimal fraction rounded to three significant figures. The calculated value is exactly $0.02$. To express this number with three significant figures, we must include trailing zeros. The first significant figure is the $2$, the second is the first $0$ after the $2$, and the third is the second $0$ after the $2$. Thus, the value is $0.0200$.\n$$\nKGR = 0.0200 \\text{ week}^{-1}\n$$\nThe second part of the task is to determine whether the criterion $KGR \\geq 0.02/\\text{week}$ is achieved. We compare our calculated value to this criterion:\n$$\n0.0200 \\text{ week}^{-1} \\geq 0.02 \\text{ week}^{-1}\n$$\nSince $0.0200$ is mathematically equal to $0.02$, the condition is met. The equality part of the \"greater than or equal to\" condition ($\\geq$) is satisfied. Therefore, the criterion for sufficient liver hypertrophy is achieved in this patient. The primary numerical answer requested is the value of the $KGR$.",
            "answer": "$$\\boxed{0.0200}$$"
        },
        {
            "introduction": "This final practice elevates the challenge from calculating individual metrics to synthesizing a complete, multi-step surgical strategy for a complex clinical case. Real-world oncologic surgery often requires balancing the need for complete tumor clearance with the physiological limits of the patient, especially in the setting of chemotherapy-associated liver injury and disease within the future remnant itself. This capstone problem challenges you to integrate the principles of volumetric assessment, regenerative kinetics, and oncologic safety to construct a coherent and evidence-based two-stage hepatectomy plan. ",
            "id": "4668250",
            "problem": "A patient with colorectal adenocarcinoma presents after $6$ cycles of oxaliplatin-based chemotherapy with bevacizumab. Imaging demonstrates bilobar colorectal liver metastases: multiple right-lobe lesions ($\\geq 5$) in segments $\\mathrm{V}$–$\\mathrm{VIII}$ abutting the right hepatic vein and right portal pedicles, and two left-lobe lesions ($\\approx 1.5\\,\\mathrm{cm}$ each) in segments $\\mathrm{II}$–$\\mathrm{III}$, both at least $1.0\\,\\mathrm{cm}$ from major inflow–outflow structures, amenable to parenchyma-sparing wedge resections. There is no extrahepatic disease. Laboratory values show bilirubin $0.8\\,\\mathrm{mg/dL}$, international normalized ratio (INR) $1.1$, platelets $220{,}000/\\mathrm{\\mu L}$, and no evidence of cirrhosis; biopsy demonstrates mild chemotherapy-associated steatohepatitis. Computed tomography (CT) volumetry reports total liver volume of $1600\\,\\mathrm{mL}$, aggregate tumor volume of $120\\,\\mathrm{mL}$, and left-lobe future liver remnant volume of $380\\,\\mathrm{mL}$ at baseline. A standardized future liver remnant is to be estimated against functional total liver volume excluding tumor burden. The surgical team intends an extended right hepatectomy (removal of segments $\\mathrm{IV}$–$\\mathrm{VIII}$, preserving segments $\\mathrm{II}$–$\\mathrm{III}$ and the caudate lobe if feasible), but the future liver remnant (FLR) harbors the small lesions noted above.\n\nConstruct a plan consistent with a two-stage hepatectomy (TSH) with portal vein embolization (PVE) that prioritizes oncologic clearance of the FLR, induces hypertrophy adequate for safe resection in a chemotherapy-exposed liver, and appropriately times the second stage. Use the following foundational facts in your reasoning: portal inflow diversion to the FLR after PVE induces hypertrophy via increased shear stress and growth-factor signaling; postoperative liver failure risk rises steeply when FLR is below widely accepted thresholds; chemotherapy-associated liver injury increases the FLR requirement compared with normal liver. Quantify remnant adequacy using standardized FLR defined against functional total liver volume excluding aggregate tumor, and judge interval growth using a weekly kinetic growth rate. Assume that post-PVE FLR volumetry at $3$ weeks measures $560\\,\\mathrm{mL}$ and that the aggregate tumor volume remains unchanged in the interval. Choose the best plan.\n\nA. Stage $1$: perform parenchyma-sparing wedge resections of segments $\\mathrm{II}$–$\\mathrm{III}$ to clear all disease from the FLR with at least $1.0\\,\\mathrm{cm}$ gross margins, preserving the left hepatic artery, left portal vein, left hepatic vein, and left bile duct; then proceed to right PVE (targeting segments $\\mathrm{IV}$–$\\mathrm{VIII}$ portal branches) within $48$–$72$ hours of recovery from stage $1$ to induce FLR hypertrophy. Monitor weekly liver function and FLR growth; proceed to Stage $2$ extended right hepatectomy once standardized FLR achieves $\\geq 30\\%$ and kinetic growth rate is $\\geq 2\\%/\\mathrm{week}$, provided no disease progression and adequate functional reserve.\n\nB. Stage $1$: perform right PVE first to induce FLR hypertrophy; after hypertrophy is achieved, perform wedge resections of segments $\\mathrm{II}$–$\\mathrm{III}$ and then proceed directly to extended right hepatectomy in the same admission, provided standardized FLR is $\\geq 20\\%$.\n\nC. Stage $1$: treat the segments $\\mathrm{II}$–$\\mathrm{III}$ lesions with percutaneous thermal ablation only, avoid surgical wedge resections; perform left PVE to shift inflow to the right lobe; then Stage $2$ right hepatectomy within $1$–$2$ weeks, provided standardized FLR is $\\geq 30\\%$.\n\nD. Stage $1$: debulk right-lobe disease with noncurative parenchyma-sparing resections to reduce tumor burden in segments $\\mathrm{V}$–$\\mathrm{VIII}$; then perform right PVE. Proceed to Stage $2$ extended right hepatectomy as soon as FLR shows any increase in volume, regardless of percentage thresholds, to minimize interval progression.\n\nE. Stage $1$: perform parenchyma-sparing wedge resections of segments $\\mathrm{II}$–$\\mathrm{III}$ plus surgical right portal vein ligation at the hilum during the same operation; plan Stage $2$ extended right hepatectomy only after standardized FLR reaches $\\geq 40\\%$, irrespective of kinetic growth rate, to be maximally conservative in a chemotherapy-exposed liver.",
            "solution": "The problem statement describes a complex clinical scenario in surgical oncology that requires careful planning based on established principles of hepatobiliary surgery. The task is to identify the most appropriate management plan from a set of options for a patient with bilobar colorectal liver metastases and a future liver remnant (FLR) that is initially too small for a safe major resection, especially in the context of chemotherapy-associated liver injury.\n\n### Step 1: Extract Givens\n\n-   **Diagnosis:** Colorectal adenocarcinoma with bilobar liver metastases.\n-   **Chemotherapy History:** $6$ cycles of oxaliplatin-based chemotherapy with bevacizumab.\n-   **Liver Histology:** Mild chemotherapy-associated steatohepatitis (CASH); no cirrhosis.\n-   **Metastasis Distribution:**\n    -   Right Lobe (to be resected): $\\geq 5$ lesions in segments $\\mathrm{V}$–$\\mathrm{VIII}$, abutting major vascular structures.\n    -   Left Lobe (FLR): $2$ lesions, $\\approx 1.5\\,\\mathrm{cm}$ each, in segments $\\mathrm{II}$–$\\mathrm{III}$, amenable to wedge resection.\n-   **Baseline CT Volumetry:**\n    -   Total Liver Volume ($TLV$): $1600\\,\\mathrm{mL}$.\n    -   Aggregate Tumor Volume ($TV$): $120\\,\\mathrm{mL}$.\n    -   Future Liver Remnant Volume ($FLR_{initial}$): $380\\,\\mathrm{mL}$.\n-   **Proposed Resection:** Extended right hepatectomy (segments $\\mathrm{IV}$–$\\mathrm{VIII}$).\n-   **Definitions and Principles:**\n    -   Strategy: Two-stage hepatectomy (TSH) with portal vein embolization (PVE).\n    -   Goal: Oncologic clearance, adequate hypertrophy for a chemotherapy-exposed liver, appropriate timing.\n    -   Standardized FLR ($sFLR$): To be calculated against functional total liver volume excluding tumor burden.\n    -   Kinetic Growth Rate ($KGR$): To be used to judge interval growth.\n    -   Chemotherapy-exposed livers require a higher FLR threshold for safety.\n-   **Assumed Post-PVE Data:**\n    -   Time to follow-up: $3$ weeks.\n    -   Post-PVE FLR Volume ($FLR_{final}$): $560\\,\\mathrm{mL}$.\n    -   Tumor volume unchanged.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement is a valid, well-constructed clinical vignette.\n\n-   **Scientifically Grounded:** The scenario is a classic challenge in modern hepatobiliary surgery. The concepts presented—TSH, PVE, FLR volumetry, $sFLR$, $KGR$, CASH, the impact of oxaliplatin on the liver, and the management of bilobar metastases—are all core tenets of the field and are based on extensive clinical evidence. The provided numerical values for labs and volumes are clinically realistic.\n-   **Well-Posed:** The problem provides sufficient data to analyze the situation quantitatively and asks for the selection of the \"best plan\" based on a set of foundational facts. A unique, best answer among the choices can be determined by applying these principles.\n-   **Objective:** The description uses standard, objective medical terminology. The foundational facts are presented as established principles for guiding the decision-making process.\n\nThe problem is free of the flaws listed in the validation checklist. It is a rigorous, formalizable problem within the domain of medical science. Therefore, the solution process can proceed.\n\n### Derivation and Solution\n\nThe core of the problem is to devise a surgical strategy that reconciles three competing objectives: $1$) achieving complete oncologic clearance (R0 resection), $2$) ensuring the patient has a sufficient volume of healthy liver remaining to prevent post-operative liver failure, and $3$) navigating the increased risk associated with a liver damaged by chemotherapy.\n\n**1. Calculation of Baseline Remnant Adequacy**\n\nFirst, we must quantify the initial state of the FLR.\nThe problem defines the standardized FLR ($sFLR$) relative to the functional total liver volume, which is the total liver volume minus the tumor volume. Let's denote this as $fTLV$.\n\n-   $fTLV = TLV - TV = 1600\\,\\mathrm{mL} - 120\\,\\mathrm{mL} = 1480\\,\\mathrm{mL}$.\n-   The initial FLR volume is $FLR_{initial} = 380\\,\\mathrm{mL}$.\n-   The baseline standardized FLR is:\n    $$sFLR_{initial} = \\frac{FLR_{initial}}{fTLV} \\times 100\\% = \\frac{380\\,\\mathrm{mL}}{1480\\,\\mathrm{mL}} \\times 100\\% \\approx 25.68\\%$$\nFor a normal, healthy liver, the minimum required $sFLR$ for a major hepatectomy is typically cited as $20\\%-25\\%$. However, the problem explicitly states that the patient has CASH after oxaliplatin-based chemotherapy. This condition impairs the liver's regenerative capacity and increases the risk of post-operative liver failure. Consequently, a higher $sFLR$ threshold of $\\geq 30\\%$, and often up to $40\\%$, is required for safety.\n\nSince the patient's baseline $sFLR$ of $\\approx 25.7\\%$ is below the required $\\geq 30\\%$ threshold, a single-stage extended right hepatectomy is contraindicated. A strategy to induce hypertrophy of the FLR is mandatory, confirming the decision for a staged approach with PVE.\n\n**2. Oncologic Considerations for a Two-Stage Hepatectomy (TSH)**\n\nThe patient has tumors within the designated FLR (segments $\\mathrm{II}$–$\\mathrm{III}$). After PVE of the right portal vein, blood flow is redirected to the left lobe, stimulating hypertrophy. This hypertrophic stimulus does not discriminate between healthy liver parenchyma and tumor cells. Therefore, performing PVE before addressing the tumors in the FLR creates a significant risk of accelerating their growth during the $3-6$ week interval required for hypertrophy.\n\nThe optimal oncologic strategy is to clear the FLR of all disease *before* inducing hypertrophy. This is the principle of the \"classic\" TSH. Stage $1$ consists of resecting the tumors in the FLR, and Stage $2$ is the major resection after the now-clean FLR has hypertrophied.\n\n**3. Assessment of Post-PVE Regeneration**\n\nThe problem provides assumed data at $3$ weeks post-PVE to evaluate the regenerative response.\n-   $FLR_{final} = 560\\,\\mathrm{mL}$.\n-   The final standardized FLR is:\n    $$sFLR_{final} = \\frac{FLR_{final}}{fTLV} \\times 100\\% = \\frac{560\\,\\mathrm{mL}}{1480\\,\\mathrm{mL}} \\times 100\\% \\approx 37.84\\%$$\nThis value of $\\approx 37.8\\%$ exceeds the minimum safe threshold of $30\\%$ for a chemotherapy-exposed liver.\n\nNext, we assess the quality of regeneration using the weekly kinetic growth rate ($KGR$).\n$$KGR = \\left( \\frac{FLR_{final} - FLR_{initial}}{FLR_{initial}} \\right) \\times \\frac{100\\%}{\\text{Time (weeks)}} $$\n$$KGR = \\left( \\frac{560\\,\\mathrm{mL} - 380\\,\\mathrm{mL}}{380\\,\\mathrm{mL}} \\right) \\times \\frac{100\\%}{3} = \\left( \\frac{180}{380} \\right) \\times \\frac{100\\%}{3} \\approx 15.79\\%\\,\\text{per week}$$\nA $KGR \\geq 2\\%/\\text{week}$ is generally considered indicative of a healthy and robust regenerative response, predicting a lower risk of post-operative liver failure. The calculated $KGR$ of $\\approx 15.8\\%/\\text{week}$ is excellent and provides strong evidence that the liver has sufficient functional reserve to tolerate the second stage.\n\n### Option-by-Option Analysis\n\n**A. Stage $1$: perform parenchyma-sparing wedge resections of segments $\\mathrm{II}$–$\\mathrm{III}$ to clear all disease from the FLR ... then proceed to right PVE ... Monitor weekly ... proceed to Stage $2$ ... once standardized FLR achieves $\\geq 30\\%$ and kinetic growth rate is $\\geq 2\\%/\\mathrm{week}$...**\n\n-   **Analysis:** This plan follows the \"classic\" TSH sequence, which is oncologically superior as it removes the tumors from the FLR before stimulating hypertrophy with PVE. The PVE is correctly targeted to the portal branches of the liver that will be resected (segments $\\mathrm{IV}$–$\\mathrm{VIII}$). The criteria for proceeding to Stage $2$ are evidence-based and appropriate for this patient: a volumetric threshold ($sFLR \\geq 30\\%$) tailored for a chemotherapy-exposed liver, and a functional kinetic threshold ($KGR \\geq 2\\%/\\text{week}$) to ensure regeneration quality. This plan correctly balances oncologic safety and the risk of liver failure.\n-   **Verdict:** Correct.\n\n**B. Stage $1$: perform right PVE first ... after hypertrophy is achieved, perform wedge resections of segments $\\mathrm{II}$–$\\mathrm{III}$ and then proceed directly to extended right hepatectomy ... provided standardized FLR is $\\geq 20\\%$.**\n\n-   **Analysis:** This plan has two major flaws. First, performing PVE before clearing the FLR tumors unnecessarily risks their progression. This is oncologically unsound. Second, the threshold of $sFLR \\geq 20\\%$ is dangerously low for a patient with CASH from oxaliplatin chemotherapy. This violates the safety principles for this clinical context.\n-   **Verdict:** Incorrect.\n\n**C. Stage $1$: treat the segments $\\mathrm{II}$–$\\mathrm{III}$ lesions with percutaneous thermal ablation only ... perform left PVE ... then Stage $2$ right hepatectomy ... provided standardized FLR is $\\geq 30\\%$.**\n\n-   **Analysis:** This plan is fundamentally illogical. The goal is to perform an extended *right* hepatectomy, which requires the *left* lobe (segments $\\mathrm{II}$–$\\mathrm{III}$) to hypertrophy. The plan proposes a *left* PVE. Embolizing the left portal vein would cause the left lobe to atrophy and the right lobe to hypertrophy—the exact opposite of what is needed. This is a critical error in surgical planning.\n-   **Verdict:** Incorrect.\n\n**D. Stage $1$: debulk right-lobe disease ... then perform right PVE. Proceed to Stage $2$ extended right hepatectomy as soon as FLR shows any increase in volume, regardless of percentage thresholds...**\n\n-   **Analysis:** This plan is reckless. It leaves the FLR tumors to grow after PVE. Much more critically, proceeding to a major hepatectomy \"regardless of percentage thresholds\" and based on \"any increase\" in volume completely ignores the well-established science of FLR volumetry for preventing post-operative liver failure. This would expose the patient to an unacceptably high risk of mortality.\n-   **Verdict:** Incorrect.\n\n**E. Stage $1$: perform parenchyma-sparing wedge resections of segments $\\mathrm{II}$–$\\mathrm{III}$ plus surgical right portal vein ligation ... during the same operation; plan Stage $2$ ... only after standardized FLR reaches $\\geq 40\\%$, irrespective of kinetic growth rate...**\n\n-   **Analysis:** This plan correctly addresses the FLR tumors first. Using surgical portal vein ligation (PVL) instead of PVE is a valid alternative, although typically more morbid. The $sFLR$ threshold of $\\geq 40\\%$ is appropriately conservative. However, the plan's major flaw is its explicit dismissal of the kinetic growth rate (\"irrespective of kinetic growth rate\"). A large FLR that is not actively regenerating (i.e., has a low $KGR$) may indicate poor functional quality and still carry a high risk of failure. $KGR$ is a crucial parameter for assessing the *quality* of the hypertrophy, not just the quantity. Ignoring it is a significant omission in modern surgical planning.\n-   **Verdict:** Incorrect.\n\n### Conclusion\n\nOption A is the only plan that correctly integrates all critical principles: it prioritizes oncologic safety by clearing the FLR before inducing hypertrophy, it uses the correct target for PVE, and it employs both volumetric ($sFLR \\geq 30\\%$) and kinetic ($KGR \\geq 2\\%/\\text{week}$) criteria to safely time the second stage of resection in a high-risk, chemotherapy-exposed liver.",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}